{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T10:10:48Z","timestamp":1789726248526,"version":"4.0.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T00:00:00Z","timestamp":1704326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T00:00:00Z","timestamp":1704326400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s12029-023-00993-6","type":"journal-article","created":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T15:02:37Z","timestamp":1704380557000},"page":"965-968","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Capecitabine-Related Thrombotic Microangiopathy"],"prefix":"10.1007","volume":"55","author":[{"given":"Francisco J. Pelegr\u00edn","family":"Mateo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Dominguez","family":"Guasch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Andr\u00e9s Guerrero","family":"Pineda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Cristina Virgili","family":"Manrique","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berta Mart\u00edn","family":"Cullell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David P\u00e1ez","family":"L\u00f3pez-Bravo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier Gavira","family":"D\u00edaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aida Piedra","family":"Casc\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xoana Barros","family":"Freiria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,4]]},"reference":[{"issue":"3","key":"993_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"993_CR2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17\u201348.","journal-title":"CA Cancer J Clin"},{"key":"993_CR3","first-page":"1","volume-title":"xPharm: the comprehensive pharmacology reference","author":"R BJ","year":"2007","unstructured":"BJ R. Capecitabine. In: Enna SJ, Bylund DB, editors. xPharm: the comprehensive pharmacology reference. New York: Elsevier; 2007. p. 1\u20134."},{"issue":"6","key":"993_CR4","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1002\/cncr.22904","volume":"110","author":"V Launay-Vacher","year":"2007","unstructured":"Launay-Vacher V, Oudard S, Janus N, Gligorov J, Pourrat X, Rixe O, et al. Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study. Cancer. 2007;110(6):1376\u201384.","journal-title":"Cancer"},{"key":"993_CR5","doi-asserted-by":"publisher","unstructured":"Gupta S, Portales-Castillo I, Daher A, Kitchlu A. Conventional chemotherapy nephrotoxicity. Adv Chronic Kidney Dis. 2021;28(5):402\u201314.e1. Available from: https:\/\/doi.org\/10.1053\/j.ackd.2021.08.001.","DOI":"10.1053\/j.ackd.2021.08.001"},{"key":"993_CR6","unstructured":"F\u0131 L, Irigoyen A, Valladares-ayerbes M, Castellanos J. Phase II study of irinotecan as first-line. 2001;704\u201311."},{"issue":"1","key":"993_CR7","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1200\/JCO.2006.08.3675","volume":"25","author":"C R\u00f6del","year":"2007","unstructured":"R\u00f6del C, Liersch T, Hermann RM, Arnold D, Reese T, Hipp M, et al. Multicenter phase II trial of chemoradiation with oxaliplatin for rectal cancer. J Clin Oncol. 2007;25(1):110\u20137.","journal-title":"J Clin Oncol"},{"issue":"6","key":"993_CR8","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1038\/sj.bjc.6603645","volume":"96","author":"F Willeke","year":"2007","unstructured":"Willeke F, Horisberger K, Kraus-Tiefenbacher U, Wenz F, Leitner A, Hochhaus A, et al. A phase II study of capecitabine and irinotecan in combination with concurrent pelvic radiotherapy (CapIri-RT) as neoadjuvant treatment of locally advanced rectal cancer. Br J Cancer. 2007;96(6):912\u20137.","journal-title":"Br J Cancer"},{"issue":"33","key":"993_CR9","doi-asserted-by":"publisher","first-page":"5335","DOI":"10.1200\/JCO.2008.16.3758","volume":"26","author":"H Wilke","year":"2008","unstructured":"Wilke H, Glynne-Jones R, Thaler J, Adenis A, Preusser P, Aguilar EA, et al. Cetuximab plus irinotecan in heavily pretreated metastatic colorectal cancer progressing on irinotecan: MABEL study. J Clin Oncol. 2008;26(33):5335\u201343.","journal-title":"J Clin Oncol"},{"key":"993_CR10","doi-asserted-by":"publisher","unstructured":"Lim AR, Kim JH, Hyun MH, Kim YH, Lee S. Prognostic factors for renal function deterioration during palliative first-line chemotherapy for metastatic colorectal cancer: a retrospective study. Support Care Cancer. 2022;30(10):8129\u201337. Available from: https:\/\/doi.org\/10.1007\/s00520-022-07249-2.","DOI":"10.1007\/s00520-022-07249-2"},{"issue":"5","key":"993_CR11","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1097\/PAP.0000000000000122","volume":"23","author":"ML Troxell","year":"2016","unstructured":"Troxell ML, Higgins JP, Kambham N. Antineoplastic treatment and renal injury: an update on renal pathology due to cytotoxic and targeted therapies. Adv Anat Pathol. 2016;23(5):310\u201329.","journal-title":"Adv Anat Pathol"},{"key":"993_CR12","doi-asserted-by":"publisher","unstructured":"Izzedine H, Perazella MA. Thrombotic microangiopathy, cancer, and cancer drugs. Am J Kidney Dis. 2015;66(5):857\u201368. Available from: https:\/\/doi.org\/10.1053\/j.ajkd.2015.02.340.","DOI":"10.1053\/j.ajkd.2015.02.340"},{"issue":"1","key":"993_CR13","doi-asserted-by":"publisher","first-page":"19","DOI":"10.2165\/00002018-200124010-00003","volume":"24","author":"PE Kintzel","year":"2001","unstructured":"Kintzel PE. Anticancer drug-induced kidney disorders: incidence, prevention and management. Drug Saf. 2001;24(1):19\u201338.","journal-title":"Drug Saf"},{"issue":"4","key":"993_CR14","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1007\/s10147-010-0050-0","volume":"15","author":"A Sonnenblick","year":"2010","unstructured":"Sonnenblick A, Meirovitz A. Renal tubular acidosis secondary to capecitabine, oxaliplatin, and cetuximab treatment in a patient with metastatic colon carcinoma: a case report and review of the literature. Int J Clin Oncol. 2010;15(4):420\u20132.","journal-title":"Int J Clin Oncol"},{"key":"993_CR15","doi-asserted-by":"crossref","unstructured":"Ferrari S, Zolezzi C, Cesari M, Fasano MC, Lamanna G BG. Prospective evaluation of high-dose ifosfamide-related nephrotoxicity in young adults patients with recurrent osteosarcoma previously treated with cisplatin, methotrexate and standard-dose ifosfamide.pdf. Anticancer Drugs. 1999;10:25\u201331.","DOI":"10.1097\/00001813-199901000-00004"},{"key":"993_CR16","doi-asserted-by":"publisher","unstructured":"Cassidy J, Twelves C, Van Cutsem E, Hoff P, Bajetta E, Boyer M, et al. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil\/leucovorin. Ann Oncol. 2002;13(4):566\u201375. Available from: https:\/\/doi.org\/10.1093\/annonc\/mdf089.","DOI":"10.1093\/annonc\/mdf089"},{"issue":"4","key":"993_CR17","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1182\/blood-2014-11-611335","volume":"125","author":"ZL Al-Nouri","year":"2015","unstructured":"Al-Nouri ZL, Reese JA, Terrell DR, Vesely SK, George JN. Drug-induced thrombotic microangiopathy: a systematic review of published reports. Blood. 2015;125(4):616\u20138.","journal-title":"Blood"},{"issue":"2","key":"993_CR18","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1111\/bcp.13808","volume":"85","author":"F Daviet","year":"2019","unstructured":"Daviet F, Rouby F, Poullin P, Moussi-Franc\u00e8s J, Sall\u00e9e M, Burtey S, et al. Thrombotic microangiopathy associated with gemcitabine use: presentation and outcome in a national French retrospective cohort. Br J Clin Pharmacol. 2019;85(2):403\u201312.","journal-title":"Br J Clin Pharmacol"},{"issue":"7","key":"993_CR19","doi-asserted-by":"publisher","first-page":"3995","DOI":"10.21873\/anticanres.14393","volume":"40","author":"ST Burns","year":"2020","unstructured":"Burns ST, Damon L, Akagi N, Laszik Z, Ko AH. Rapid improvement in gemcitabine-associated thrombotic microangiopathy after a single dose of eculizumab: case report and review of the literature. Anticancer Res. 2020;40(7):3995\u20134000.","journal-title":"Anticancer Res"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-023-00993-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-023-00993-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-023-00993-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T01:06:09Z","timestamp":1718845569000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-023-00993-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,4]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["993"],"URL":"https:\/\/doi.org\/10.1007\/s12029-023-00993-6","relation":{},"ISSN":["1941-6628","1941-6636"],"issn-type":[{"value":"1941-6628","type":"print"},{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,4]]},"assertion":[{"value":"19 November 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}